Boronic Acid Transition State Inhibitors as Potent Inactivators of KPC and CTX-M β-Lactamases: Biochemical and Structural Analyses

Autores
Alsenani, Tahani A.; Rodríguez, María Margarita; Ghiglione, Barbara; Taracila, Magdalena A.; Mojica, Maria F.; Rojas, Laura J.; Hujer, Andrea M.; Gutkind, Gabriel Osvaldo; Bethel, Christopher R.; Rather, Philip N.; Introvigne, Maria Luisa; Prati, Fabio; Caselli, Emilia; Power, Pablo; van den Akker, Focco; Bonomo, Robert A.
Año de publicación
2023
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Design of novel β-lactamase inhibitors (BLIs) is one of the currently accepted strategies to combat the threat of cephalosporin and carbapenem resistance in Gram-negative bacteria. Boronic acid transition state inhibitors (BATSIs) are competitive, reversible BLIs that offer promise as novel therapeutic agents. In this study, the activities of two α-amido-β-triazolylethaneboronic acid transition state inhibitors (S02030 and MB_076) targeting representative KPC (KPC-2) and CTX-M (CTX-M-96, a CTX-M-15-type extended-spectrum β-lactamase [ESBL]) β-lactamases were evaluated. The 50% inhibitory concentrations (IC50s) for both inhibitors were measured in the nanomolar range (2 to 135 nM). For S02030, the k2/K for CTX-M-96 (24,000 M21 s21) was twice the reported value for KPC-2 (12,000 M21 s21); for MB_076, the k2/K values ranged from 1,200 M21 s21 (KPC-2) to 3,900 M21 s21 (CTX-M-96). Crystal structures of KPC-2 with MB_076 (1.38-Å resolution) and S02030 and the in silico models of CTX-M-96 with these two BATSIs show that interaction in the CTX-M-96–S02030 and CTX-M-96–MB_076 complexes were overall equivalent to that observed for the crystallographic structure of KPC-2–S02030 and KPC-2–MB_076. The tetrahedral interaction surrounding the boron atom from S02030 and MB_076 creates a favorable hydrogen bonding network with S70, S130, N132, N170, and S237. However, the changes from W105 in KPC-2 to Y105 in CTX-M-96 and the missing residue R220 in CTX-M-96 alter the arrangement of the inhibitors in the active site of CTX-M-96, partially explaining the difference in kinetic parameters. The novel BATSI scaffolds studied here advance our understanding of structure-activity relationships (SARs) and illustrate the importance of new approaches to β-lactamase inhibitor design.
Fil: Alsenani, Tahani A.. Case Western Reserve University School of Medicine; Estados Unidos
Fil: Rodríguez, María Margarita. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Investigaciones en Bacteriología y Virología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
Fil: Ghiglione, Barbara. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Investigaciones en Bacteriología y Virología Molecular; Argentina
Fil: Taracila, Magdalena A.. Case Western Reserve University School of Medicine; Estados Unidos. Louis Stokes Cleveland Department of Veterans Affairs Medical Center; Estados Unidos
Fil: Mojica, Maria F.. Louis Stokes Cleveland Department of Veterans Affairs Medical Center; Estados Unidos. Case Western Reserve University School of Medicine; Estados Unidos. Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology; Estados Unidos
Fil: Rojas, Laura J.. Louis Stokes Cleveland Department of Veterans Affairs Medical Center; Estados Unidos. Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology; Estados Unidos. Case Western Reserve University School of Medicine; Estados Unidos
Fil: Hujer, Andrea M.. Case Western Reserve University School of Medicine; Estados Unidos. Louis Stokes Cleveland Department of Veterans Affairs Medical Center; Estados Unidos
Fil: Gutkind, Gabriel Osvaldo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Investigaciones en Bacteriología y Virología Molecular; Argentina
Fil: Bethel, Christopher R.. Louis Stokes Cleveland Department of Veterans Affairs Medical Center; Estados Unidos
Fil: Rather, Philip N.. University of Emory; Estados Unidos. Atlanta VA Medical Center; Estados Unidos
Fil: Introvigne, Maria Luisa. Università di Modena e Reggio Emilia; Italia
Fil: Prati, Fabio. Università di Modena e Reggio Emilia; Italia
Fil: Caselli, Emilia. Università di Modena e Reggio Emilia; Italia
Fil: Power, Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Investigaciones en Bacteriología y Virología Molecular; Argentina
Fil: van den Akker, Focco. Case Western Reserve University School of Medicine; Estados Unidos
Fil: Bonomo, Robert A.. Case Western Reserve University School of Medicine; Estados Unidos. Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology; Estados Unidos
Materia
BORONATE
CARBAPENEMASE
CTX-M
CTX-M-96
ESBL
KPC
KPC-2
MB_076
S02030
Β-LACTAMASES
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/225318

id CONICETDig_cd3c52269e15a95f3ce46ef3e290f261
oai_identifier_str oai:ri.conicet.gov.ar:11336/225318
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Boronic Acid Transition State Inhibitors as Potent Inactivators of KPC and CTX-M β-Lactamases: Biochemical and Structural AnalysesAlsenani, Tahani A.Rodríguez, María MargaritaGhiglione, BarbaraTaracila, Magdalena A.Mojica, Maria F.Rojas, Laura J.Hujer, Andrea M.Gutkind, Gabriel OsvaldoBethel, Christopher R.Rather, Philip N.Introvigne, Maria LuisaPrati, FabioCaselli, EmiliaPower, Pablovan den Akker, FoccoBonomo, Robert A.BORONATECARBAPENEMASECTX-MCTX-M-96ESBLKPCKPC-2MB_076S02030Β-LACTAMASEShttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Design of novel β-lactamase inhibitors (BLIs) is one of the currently accepted strategies to combat the threat of cephalosporin and carbapenem resistance in Gram-negative bacteria. Boronic acid transition state inhibitors (BATSIs) are competitive, reversible BLIs that offer promise as novel therapeutic agents. In this study, the activities of two α-amido-β-triazolylethaneboronic acid transition state inhibitors (S02030 and MB_076) targeting representative KPC (KPC-2) and CTX-M (CTX-M-96, a CTX-M-15-type extended-spectrum β-lactamase [ESBL]) β-lactamases were evaluated. The 50% inhibitory concentrations (IC50s) for both inhibitors were measured in the nanomolar range (2 to 135 nM). For S02030, the k2/K for CTX-M-96 (24,000 M21 s21) was twice the reported value for KPC-2 (12,000 M21 s21); for MB_076, the k2/K values ranged from 1,200 M21 s21 (KPC-2) to 3,900 M21 s21 (CTX-M-96). Crystal structures of KPC-2 with MB_076 (1.38-Å resolution) and S02030 and the in silico models of CTX-M-96 with these two BATSIs show that interaction in the CTX-M-96–S02030 and CTX-M-96–MB_076 complexes were overall equivalent to that observed for the crystallographic structure of KPC-2–S02030 and KPC-2–MB_076. The tetrahedral interaction surrounding the boron atom from S02030 and MB_076 creates a favorable hydrogen bonding network with S70, S130, N132, N170, and S237. However, the changes from W105 in KPC-2 to Y105 in CTX-M-96 and the missing residue R220 in CTX-M-96 alter the arrangement of the inhibitors in the active site of CTX-M-96, partially explaining the difference in kinetic parameters. The novel BATSI scaffolds studied here advance our understanding of structure-activity relationships (SARs) and illustrate the importance of new approaches to β-lactamase inhibitor design.Fil: Alsenani, Tahani A.. Case Western Reserve University School of Medicine; Estados UnidosFil: Rodríguez, María Margarita. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Investigaciones en Bacteriología y Virología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; ArgentinaFil: Ghiglione, Barbara. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Investigaciones en Bacteriología y Virología Molecular; ArgentinaFil: Taracila, Magdalena A.. Case Western Reserve University School of Medicine; Estados Unidos. Louis Stokes Cleveland Department of Veterans Affairs Medical Center; Estados UnidosFil: Mojica, Maria F.. Louis Stokes Cleveland Department of Veterans Affairs Medical Center; Estados Unidos. Case Western Reserve University School of Medicine; Estados Unidos. Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology; Estados UnidosFil: Rojas, Laura J.. Louis Stokes Cleveland Department of Veterans Affairs Medical Center; Estados Unidos. Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology; Estados Unidos. Case Western Reserve University School of Medicine; Estados UnidosFil: Hujer, Andrea M.. Case Western Reserve University School of Medicine; Estados Unidos. Louis Stokes Cleveland Department of Veterans Affairs Medical Center; Estados UnidosFil: Gutkind, Gabriel Osvaldo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Investigaciones en Bacteriología y Virología Molecular; ArgentinaFil: Bethel, Christopher R.. Louis Stokes Cleveland Department of Veterans Affairs Medical Center; Estados UnidosFil: Rather, Philip N.. University of Emory; Estados Unidos. Atlanta VA Medical Center; Estados UnidosFil: Introvigne, Maria Luisa. Università di Modena e Reggio Emilia; ItaliaFil: Prati, Fabio. Università di Modena e Reggio Emilia; ItaliaFil: Caselli, Emilia. Università di Modena e Reggio Emilia; ItaliaFil: Power, Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Investigaciones en Bacteriología y Virología Molecular; ArgentinaFil: van den Akker, Focco. Case Western Reserve University School of Medicine; Estados UnidosFil: Bonomo, Robert A.. Case Western Reserve University School of Medicine; Estados Unidos. Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology; Estados UnidosAmerican Society for Microbiology2023-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/225318Alsenani, Tahani A.; Rodríguez, María Margarita; Ghiglione, Barbara; Taracila, Magdalena A.; Mojica, Maria F.; et al.; Boronic Acid Transition State Inhibitors as Potent Inactivators of KPC and CTX-M β-Lactamases: Biochemical and Structural Analyses; American Society for Microbiology; Antimicrobial Agents and Chemotherapy; 67; 1; 1-2023; 1-100066-4804CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://journals.asm.org/doi/10.1128/aac.00930-22info:eu-repo/semantics/altIdentifier/doi/10.1128/aac.00930-22info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:45:30Zoai:ri.conicet.gov.ar:11336/225318instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:45:31.091CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Boronic Acid Transition State Inhibitors as Potent Inactivators of KPC and CTX-M β-Lactamases: Biochemical and Structural Analyses
title Boronic Acid Transition State Inhibitors as Potent Inactivators of KPC and CTX-M β-Lactamases: Biochemical and Structural Analyses
spellingShingle Boronic Acid Transition State Inhibitors as Potent Inactivators of KPC and CTX-M β-Lactamases: Biochemical and Structural Analyses
Alsenani, Tahani A.
BORONATE
CARBAPENEMASE
CTX-M
CTX-M-96
ESBL
KPC
KPC-2
MB_076
S02030
Β-LACTAMASES
title_short Boronic Acid Transition State Inhibitors as Potent Inactivators of KPC and CTX-M β-Lactamases: Biochemical and Structural Analyses
title_full Boronic Acid Transition State Inhibitors as Potent Inactivators of KPC and CTX-M β-Lactamases: Biochemical and Structural Analyses
title_fullStr Boronic Acid Transition State Inhibitors as Potent Inactivators of KPC and CTX-M β-Lactamases: Biochemical and Structural Analyses
title_full_unstemmed Boronic Acid Transition State Inhibitors as Potent Inactivators of KPC and CTX-M β-Lactamases: Biochemical and Structural Analyses
title_sort Boronic Acid Transition State Inhibitors as Potent Inactivators of KPC and CTX-M β-Lactamases: Biochemical and Structural Analyses
dc.creator.none.fl_str_mv Alsenani, Tahani A.
Rodríguez, María Margarita
Ghiglione, Barbara
Taracila, Magdalena A.
Mojica, Maria F.
Rojas, Laura J.
Hujer, Andrea M.
Gutkind, Gabriel Osvaldo
Bethel, Christopher R.
Rather, Philip N.
Introvigne, Maria Luisa
Prati, Fabio
Caselli, Emilia
Power, Pablo
van den Akker, Focco
Bonomo, Robert A.
author Alsenani, Tahani A.
author_facet Alsenani, Tahani A.
Rodríguez, María Margarita
Ghiglione, Barbara
Taracila, Magdalena A.
Mojica, Maria F.
Rojas, Laura J.
Hujer, Andrea M.
Gutkind, Gabriel Osvaldo
Bethel, Christopher R.
Rather, Philip N.
Introvigne, Maria Luisa
Prati, Fabio
Caselli, Emilia
Power, Pablo
van den Akker, Focco
Bonomo, Robert A.
author_role author
author2 Rodríguez, María Margarita
Ghiglione, Barbara
Taracila, Magdalena A.
Mojica, Maria F.
Rojas, Laura J.
Hujer, Andrea M.
Gutkind, Gabriel Osvaldo
Bethel, Christopher R.
Rather, Philip N.
Introvigne, Maria Luisa
Prati, Fabio
Caselli, Emilia
Power, Pablo
van den Akker, Focco
Bonomo, Robert A.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv BORONATE
CARBAPENEMASE
CTX-M
CTX-M-96
ESBL
KPC
KPC-2
MB_076
S02030
Β-LACTAMASES
topic BORONATE
CARBAPENEMASE
CTX-M
CTX-M-96
ESBL
KPC
KPC-2
MB_076
S02030
Β-LACTAMASES
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv Design of novel β-lactamase inhibitors (BLIs) is one of the currently accepted strategies to combat the threat of cephalosporin and carbapenem resistance in Gram-negative bacteria. Boronic acid transition state inhibitors (BATSIs) are competitive, reversible BLIs that offer promise as novel therapeutic agents. In this study, the activities of two α-amido-β-triazolylethaneboronic acid transition state inhibitors (S02030 and MB_076) targeting representative KPC (KPC-2) and CTX-M (CTX-M-96, a CTX-M-15-type extended-spectrum β-lactamase [ESBL]) β-lactamases were evaluated. The 50% inhibitory concentrations (IC50s) for both inhibitors were measured in the nanomolar range (2 to 135 nM). For S02030, the k2/K for CTX-M-96 (24,000 M21 s21) was twice the reported value for KPC-2 (12,000 M21 s21); for MB_076, the k2/K values ranged from 1,200 M21 s21 (KPC-2) to 3,900 M21 s21 (CTX-M-96). Crystal structures of KPC-2 with MB_076 (1.38-Å resolution) and S02030 and the in silico models of CTX-M-96 with these two BATSIs show that interaction in the CTX-M-96–S02030 and CTX-M-96–MB_076 complexes were overall equivalent to that observed for the crystallographic structure of KPC-2–S02030 and KPC-2–MB_076. The tetrahedral interaction surrounding the boron atom from S02030 and MB_076 creates a favorable hydrogen bonding network with S70, S130, N132, N170, and S237. However, the changes from W105 in KPC-2 to Y105 in CTX-M-96 and the missing residue R220 in CTX-M-96 alter the arrangement of the inhibitors in the active site of CTX-M-96, partially explaining the difference in kinetic parameters. The novel BATSI scaffolds studied here advance our understanding of structure-activity relationships (SARs) and illustrate the importance of new approaches to β-lactamase inhibitor design.
Fil: Alsenani, Tahani A.. Case Western Reserve University School of Medicine; Estados Unidos
Fil: Rodríguez, María Margarita. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Investigaciones en Bacteriología y Virología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
Fil: Ghiglione, Barbara. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Investigaciones en Bacteriología y Virología Molecular; Argentina
Fil: Taracila, Magdalena A.. Case Western Reserve University School of Medicine; Estados Unidos. Louis Stokes Cleveland Department of Veterans Affairs Medical Center; Estados Unidos
Fil: Mojica, Maria F.. Louis Stokes Cleveland Department of Veterans Affairs Medical Center; Estados Unidos. Case Western Reserve University School of Medicine; Estados Unidos. Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology; Estados Unidos
Fil: Rojas, Laura J.. Louis Stokes Cleveland Department of Veterans Affairs Medical Center; Estados Unidos. Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology; Estados Unidos. Case Western Reserve University School of Medicine; Estados Unidos
Fil: Hujer, Andrea M.. Case Western Reserve University School of Medicine; Estados Unidos. Louis Stokes Cleveland Department of Veterans Affairs Medical Center; Estados Unidos
Fil: Gutkind, Gabriel Osvaldo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Investigaciones en Bacteriología y Virología Molecular; Argentina
Fil: Bethel, Christopher R.. Louis Stokes Cleveland Department of Veterans Affairs Medical Center; Estados Unidos
Fil: Rather, Philip N.. University of Emory; Estados Unidos. Atlanta VA Medical Center; Estados Unidos
Fil: Introvigne, Maria Luisa. Università di Modena e Reggio Emilia; Italia
Fil: Prati, Fabio. Università di Modena e Reggio Emilia; Italia
Fil: Caselli, Emilia. Università di Modena e Reggio Emilia; Italia
Fil: Power, Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Investigaciones en Bacteriología y Virología Molecular; Argentina
Fil: van den Akker, Focco. Case Western Reserve University School of Medicine; Estados Unidos
Fil: Bonomo, Robert A.. Case Western Reserve University School of Medicine; Estados Unidos. Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology; Estados Unidos
description Design of novel β-lactamase inhibitors (BLIs) is one of the currently accepted strategies to combat the threat of cephalosporin and carbapenem resistance in Gram-negative bacteria. Boronic acid transition state inhibitors (BATSIs) are competitive, reversible BLIs that offer promise as novel therapeutic agents. In this study, the activities of two α-amido-β-triazolylethaneboronic acid transition state inhibitors (S02030 and MB_076) targeting representative KPC (KPC-2) and CTX-M (CTX-M-96, a CTX-M-15-type extended-spectrum β-lactamase [ESBL]) β-lactamases were evaluated. The 50% inhibitory concentrations (IC50s) for both inhibitors were measured in the nanomolar range (2 to 135 nM). For S02030, the k2/K for CTX-M-96 (24,000 M21 s21) was twice the reported value for KPC-2 (12,000 M21 s21); for MB_076, the k2/K values ranged from 1,200 M21 s21 (KPC-2) to 3,900 M21 s21 (CTX-M-96). Crystal structures of KPC-2 with MB_076 (1.38-Å resolution) and S02030 and the in silico models of CTX-M-96 with these two BATSIs show that interaction in the CTX-M-96–S02030 and CTX-M-96–MB_076 complexes were overall equivalent to that observed for the crystallographic structure of KPC-2–S02030 and KPC-2–MB_076. The tetrahedral interaction surrounding the boron atom from S02030 and MB_076 creates a favorable hydrogen bonding network with S70, S130, N132, N170, and S237. However, the changes from W105 in KPC-2 to Y105 in CTX-M-96 and the missing residue R220 in CTX-M-96 alter the arrangement of the inhibitors in the active site of CTX-M-96, partially explaining the difference in kinetic parameters. The novel BATSI scaffolds studied here advance our understanding of structure-activity relationships (SARs) and illustrate the importance of new approaches to β-lactamase inhibitor design.
publishDate 2023
dc.date.none.fl_str_mv 2023-01
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/225318
Alsenani, Tahani A.; Rodríguez, María Margarita; Ghiglione, Barbara; Taracila, Magdalena A.; Mojica, Maria F.; et al.; Boronic Acid Transition State Inhibitors as Potent Inactivators of KPC and CTX-M β-Lactamases: Biochemical and Structural Analyses; American Society for Microbiology; Antimicrobial Agents and Chemotherapy; 67; 1; 1-2023; 1-10
0066-4804
CONICET Digital
CONICET
url http://hdl.handle.net/11336/225318
identifier_str_mv Alsenani, Tahani A.; Rodríguez, María Margarita; Ghiglione, Barbara; Taracila, Magdalena A.; Mojica, Maria F.; et al.; Boronic Acid Transition State Inhibitors as Potent Inactivators of KPC and CTX-M β-Lactamases: Biochemical and Structural Analyses; American Society for Microbiology; Antimicrobial Agents and Chemotherapy; 67; 1; 1-2023; 1-10
0066-4804
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://journals.asm.org/doi/10.1128/aac.00930-22
info:eu-repo/semantics/altIdentifier/doi/10.1128/aac.00930-22
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv American Society for Microbiology
publisher.none.fl_str_mv American Society for Microbiology
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842268736279543808
score 13.13397